Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin (NCT07682454)
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
🩺 Plain-English Summary (8th-Grade Level)
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.
Who can join: Review the eligibility criteria below.
Location: Zuckerberg San Francisco General Hospital (ZSFG) — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Zuckerberg San Francisco General Hospital (ZSFG) — San Francisco, California
- University of California, San Francisco — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 514-6221
Email: diana.flores@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma (HCC)
- Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE — Aurora, Colorado
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
- Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
- Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California
Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.